MX340574B - Imidazo pirazinas. - Google Patents

Imidazo pirazinas.

Info

Publication number
MX340574B
MX340574B MX2013010183A MX2013010183A MX340574B MX 340574 B MX340574 B MX 340574B MX 2013010183 A MX2013010183 A MX 2013010183A MX 2013010183 A MX2013010183 A MX 2013010183A MX 340574 B MX340574 B MX 340574B
Authority
MX
Mexico
Prior art keywords
pyrazines
imidazo
compounds
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
MX2013010183A
Other languages
English (en)
Other versions
MX2013010183A (es
Inventor
Thomas Luk Kin-Chun
Soth Michael
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013010183A publication Critical patent/MX2013010183A/es
Publication of MX340574B publication Critical patent/MX340574B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan los compuestos de la fórmula (ver Fórmula) y sus sales farmacéuticas aceptables se describen, así como las composiciones farmacéuticas que contienen dichos compuestos y sus sales farmacéuticas aceptables, y el uso de dichos compuestos y composiciones farmacéuticas para el tratamiento, control o mejora de AML.
MX2013010183A 2011-03-17 2012-03-14 Imidazo pirazinas. MX340574B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453601P 2011-03-17 2011-03-17
PCT/EP2012/054415 WO2012123470A1 (en) 2011-03-17 2012-03-14 Imidazo pyrazines

Publications (2)

Publication Number Publication Date
MX2013010183A MX2013010183A (es) 2013-10-03
MX340574B true MX340574B (es) 2016-07-13

Family

ID=45855775

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010183A MX340574B (es) 2011-03-17 2012-03-14 Imidazo pirazinas.

Country Status (11)

Country Link
US (1) US8673905B2 (es)
EP (1) EP2686319B1 (es)
JP (1) JP5796094B2 (es)
KR (1) KR101561756B1 (es)
CN (1) CN103429593B (es)
BR (1) BR112013019160A2 (es)
CA (1) CA2830131A1 (es)
ES (1) ES2590928T3 (es)
MX (1) MX340574B (es)
RU (1) RU2600327C2 (es)
WO (1) WO2012123470A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9653770B2 (en) 2014-10-21 2017-05-16 At&T Intellectual Property I, L.P. Guided wave coupler, coupling module and methods for use therewith
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US10065963B2 (en) 2015-11-06 2018-09-04 Incyte Corporation Heterocyclic compounds as PI3K-γ inhibitors
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
US10138248B2 (en) 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
JP7352807B2 (ja) 2017-04-12 2023-09-29 マジェンタ セラピューティクス インコーポレイテッド アリール炭化水素受容体アンタゴニスト及びその使用
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA
IL312674A (en) 2018-01-29 2024-07-01 Merck Patent Gmbh GCN2 inhibitors and uses thereof
EP3746075B1 (en) * 2018-01-29 2025-09-03 Merck Patent GmbH Gcn2 inhibitors and uses thereof
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
AU2020311297A1 (en) * 2019-07-10 2022-02-03 Aucentra Therapeutics Pty Ltd DERIVATIVES OF 4-(IMIDAZO[l,2-a]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS
CN111646978B (zh) * 2020-06-11 2021-12-21 浙江大学 N2-取代烷氧芳环-2-氨基嘧啶类衍生物及应用
MX2023006938A (es) * 2020-12-23 2023-10-13 Childrens Hospital Med Ct Compuestos inhibidores multicíclicos de la cinasa asociada al receptor de interleucina-1 (irak) y la tirosina cinasa 3 similar a fms (flt3) y usos de estos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
AU2005278292B2 (en) * 2004-08-31 2011-09-08 Msd K.K. Novel substituted imidazole derivatives
US20070055743A1 (en) 2005-09-02 2007-03-08 Pirtle Ross M Remote control media player
US7709468B2 (en) * 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
CA2660836A1 (en) * 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
AU2007311480A1 (en) 2006-10-16 2008-04-24 Forma Therapeutics, Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
MX2009005011A (es) * 2006-11-08 2009-05-20 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa.
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN101772500A (zh) * 2007-06-14 2010-07-07 先灵公司 作为蛋白质激酶抑制剂的咪唑并吡嗪
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
BRPI0912668A2 (pt) * 2008-05-13 2016-01-26 Irm Llc composto e composições como inibidores de quinase

Also Published As

Publication number Publication date
CN103429593A (zh) 2013-12-04
US8673905B2 (en) 2014-03-18
CA2830131A1 (en) 2012-09-20
EP2686319B1 (en) 2016-07-13
CN103429593B (zh) 2015-09-09
JP2014508180A (ja) 2014-04-03
ES2590928T3 (es) 2016-11-24
EP2686319A1 (en) 2014-01-22
US20120238564A1 (en) 2012-09-20
JP5796094B2 (ja) 2015-10-21
BR112013019160A2 (pt) 2016-10-04
KR101561756B1 (ko) 2015-10-19
HK1187614A1 (zh) 2014-04-11
MX2013010183A (es) 2013-10-03
KR20130133870A (ko) 2013-12-09
WO2012123470A1 (en) 2012-09-20
RU2013142881A (ru) 2015-04-27
RU2600327C2 (ru) 2016-10-20

Similar Documents

Publication Publication Date Title
MX340574B (es) Imidazo pirazinas.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
IN2014MN02598A (es)
IN2015DN01119A (es)
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
IN2014DN09434A (es)
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
TN2015000034A1 (en) Derivatives of azaindazole or diazaindazole type for treating pain
WO2013004995A8 (en) Pyrimidinone compounds and their use
GB201209587D0 (en) Therapeutic compounds
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
PH12015501609A1 (en) Phenicol antibacterials
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
TW201613864A (en) Novel compounds
PH12015501088A1 (en) Dimeric compounds
MX2012008328A (es) Derivados de pirazina.
IN2014DN09347A (es)
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2014062838A3 (en) Pkm2 modulators and methods for their use
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.

Legal Events

Date Code Title Description
FG Grant or registration